Human Genome Sciences

Companies Human Genome Sciences

News Human Genome Sciences

• arGEN-X appoints Dr Debbie Allen as Senior Director Business Development

  arGEN-X BV announced the appointment of Dr Debbie Allen as Senior Director Business Development. Dr Allen brings to arGEN-X more than 12 years of corporate and business development experience with small and large biotech companies. Dr Allen established her Business Development career at Cambridge A more

• Novartis discontinues development of two investigational compounds

  Novartis announced that it discontinued the development of two investigational compounds in its pharmaceutical pipeline, reflecting enhanced focus on differentiated medicines most likely to address unmet medical needs. Novartis and Human Genome Sciences decided to stop further global development of more

• GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta

  GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE). A priority review designation is granted to drugs more

Publications Human Genome Sciences

• Seven days: 13–19 July 2012

  Seven days: 13–19 July 2012 Nature 487, 7407 (2012). http://www.nature.com/doifinder/10.1038/487276a The week in science: FDA spied on employees; GSK buys up Human Genome Sciences; and Hubble finds a fifth moon around Pluto. more

• Deal watch: HGS and FivePrime in FGF 'ligand trap' deal

  Deal watch: HGS and FivePrime in FGF 'ligand trap' deal Nature Reviews Drug Discovery 10, 328 (2011). doi:10.1038/nrd3448 Human Genome Sciences (HGS) and FivePrime Therapeutics have entered into an agreement to develop and commercialize FP-1039, a fibroblast growth factor (FGF more

• Belimumab

  Belimumab Nature Reviews Drug Discovery 10, 335 (2011). doi:10.1038/nrd3436 Authors: Iñaki Sanz, Uma Yasothan & Peter Kirkpatrick In March 2011, belimumab (Benlysta; Human Genome Sciences/GlaxoSmithKline), a human monoclonal antibody that is specific for the cytokine B lympho more

Market studies Human Genome Sciences

• R&D Trends: Systemic Lupus Erythematosus - Benlysta’s FDA approval provides hope for disease treatment, future trial design, and other pipeline candidates

  Introduction There remains considerable debate over the optimum efficacy measure and clinical trial design in SLE. While the SLE Responder Index has proved successful in demonstrating the efficacy of Benlysta (belimumab; Human Genome Sciences/GlaxoSmithKline) such that many other trials are now fol more

• World Biological Drugs Market 2011-2021

  Do you want to find market prospects for products and companies in the biological drugs industry? Our new report shows you biopharma revenue forecasts for 2011 to 2021. We provide original research, data and opinions to benefit your work now. What revenues will biopharmaceutical markets achieve fro more

• Myriad Genetics, Inc. (MYGN) - Financial and Strategic SWOT Analysis Review

  Myriad Genetics, Inc. (MYGN) - Financial and Strategic SWOT Analysis Review Summary Myriad Genetics, Inc. (Myriad) is a research focused biotechnology company engaged in the development and commercialization of small molecular diagnostic products. The company offers different medicine products to more

Websites Human Genome Sciences